|
1
|
Grivennikov SI: Inflammation and
colorectal cancer: Colitis-associated neoplasia. Semin
Immunopathol. 35:229–244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lakatos PL and Lakatos L: Risk for
colorectal cancer in ulcerative colitis: Changes, causes and
management strategies. World J Gastroenterol. 14:3937–3947. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ullman TA and Itzkowitz SH: Intestinal
inflammation and cancer. Gastroenterology. 140:1807–1816. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Waldner MJ and Neurath MF: Cytokines in
colitis associated cancer: Potential drug targets? Inflamm Allergy
Drug Targets. 7:187–194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dubois RN: Role of inflammation and
inflammatory mediators in colorectal cancer. Trans Am Clin Climatol
Assoc. 125:358–373. 2014.PubMed/NCBI
|
|
6
|
Li Y, Deuring J, Peppelenbosch MP, Kuipers
EJ, de Haar C and van der Woude CJ: IL-6-induced DNMT1 activity
mediates SOCS3 promoter hypermethylation in ulcerative
colitis-related colorectal cancer. Carcinogenesis. 33:1889–1896.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Qi H, Yang H, Xu G, Ren J, Hua W, Shi Y,
Torsvik M, Florholmen J and Cui G: Therapeutic efficacy of IL-17A
antibody injection in preventing the development of colitis
associated carcinogenesis in mice. Immunobiology. 220:54–59. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Waldner MJ, Foersch S and Neurath MF:
Interleukin-6-a key regulator of colorectal cancer development. Int
J Biol Sci. 8:1248–1253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, de Haar C, Chen M, Deuring J,
Gerrits MM, Smits R, Xia B, Kuipers EJ and van der Woude CJ:
Disease-related expression of the IL6/STAT3/SOCS3 signalling
pathway in ulcerative colitis and ulcerative colitis-related
carcinogenesis. Gut. 59:227–235. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Monti E and Gariboldi MB: HIF-1 as a
target for cancer chemotherapy, chemosensitization and
chemoprevention. Curr Mol Pharmacol. 4:62–77. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feldser D, Agani F, Iyer NV, Pak B,
Ferreira G and Semenza GL: Reciprocal positive regulation of
hypoxia-inducible factor 1alpha and insulin-like growth factor 2.
Cancer Res. 59:3915–3918. 1999.PubMed/NCBI
|
|
13
|
Laughner E, Taghavi P, Chiles K, Mahon PC
and Semenza GL: HER2 (neu) signaling increases the rate of
hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel
mechanism for HIF-1-mediated vascular endothelial growth factor
expression. Mol Cell Biol. 21:3995–4004. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hellwig-Bürgel T, Rutkowski K, Metzen E,
Fandrey J and Jelkmann W: Interleukin-1beta and tumor necrosis
factor-alpha stimulate DNA binding of hypoxia-inducible factor-1.
Blood. 94:1561–1567. 1999.PubMed/NCBI
|
|
15
|
Chen C, Pore N, Behrooz A, Ismail-Beigi F
and Maity A: Regulation of glut1 mRNA by hypoxia-inducible
factor-1. Interaction between H-ras and hypoxia. J Biol Chem.
276:9519–9525. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zundel W, Schindler C, Haas-Kogan D, Koong
A, Kaper F, Chen E, Gottschalk AR, Ryan HE, Johnson RS, Jefferson
AB, et al: Loss of PTEN facilitates HIF-1-mediated gene expression.
Genes Dev. 14:391–396. 2000.PubMed/NCBI
|
|
17
|
Liao D and Johnson RS: Hypoxia: A key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Semenza GL: Defining the role of
hypoxia-inducible factor 1 in cancer biology and therapeutics.
Oncogene. 29:625–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: Role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Krishnamachary B, Berg-Dixon S, Kelly B,
Agani F, Feldser D, Ferreira G, Iyer N, LaRusch J, Pak B, Taghavi P
and Semenza GL: Regulation of colon carcinoma cell invasion by
hypoxia-inducible factor 1. Cancer Res. 63:1138–1143.
2003.PubMed/NCBI
|
|
21
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
22
|
Mariani F, Sena P, Marzona L, Riccio M,
Fano R, Manni P, Gregorio CD, Pezzi A, Leon MP, Monni S, et al:
Cyclooxygenase-2 and Hypoxia-Inducible Factor-1alpha protein
expression is related to inflammation, and up-regulated since the
early steps of colorectal carcinogenesis. Cancer Lett. 279:221–229.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fransén K, Fenech M, Fredrikson M,
Dabrosin C and Söderkvist P: Association between ulcerative growth
and hypoxia inducible factor-1alpha polymorphisms in colorectal
cancer patients. Mol Carcinog. 45:833–840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Neufert C, Becker C and Neurath MF: An
inducible mouse model of colon carcinogenesis for the analysis of
sporadic and inflammation-driven tumor progression. Nat Protoc.
2:1998–2004. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan L, Han J, Meng Q, Xi Q, Zhuang Q,
Jiang Y, Han Y, Zhang B, Fang J and Wu G: Muscle-specific E3
ubiquitin ligases are involved in muscle atrophy of cancer
cachexia: An in vitro and in vivo study. Oncol Rep. 33:2261–2268.
2015.PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Grivennikov SI and Karin M: Inflammation
and oncogenesis: A vicious connection. Curr Opin Genet Dev.
20:65–71. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suzuki R, Kohno H, Sugie S, Nakagama H and
Tanaka T: Strain differences in the susceptibility to azoxymethane
and dextran sodium sulfate-induced colon carcinogenesis in mice.
Carcinogenesis. 27:162–169. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Becker C, Fantini MC, Schramm C, Lehr HA,
Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, et al:
TGF-beta suppresses tumor progression in colon cancer by inhibition
of IL-6 trans-signaling. Immunity. 21:491–501. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Middleton K, Jones J, Lwin Z and Coward
JI: Interleukin-6: An angiogenic target in solid tumours. Crit Rev
Oncol Hematol. 89:129–139. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bataille R, Barlogie B, Lu ZY, Rossi JF,
Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J and Klein B:
Biologic effects of anti-interleukin-6 murine monoclonal antibody
in advanced multiple myeloma. Blood. 86:685–691. 1995.PubMed/NCBI
|
|
32
|
Racadot E, Audhuy B, Duvernoy H, Thyss A,
Lang JM, Wijdenes J and Hervé P: Clinical and immunological
follow-up of patients with AIDS-associated Kaposi's sarcoma treated
with an anti-IL-6 monoclonal antibody. Cytokines Mol Ther.
1:133–138. 1995.PubMed/NCBI
|
|
33
|
van Rhee F, Wong RS, Munshi N, Rossi JF,
Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, et al:
Siltuximab for multicentric Castleman's disease: A randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 15:966–974.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rossi JF, Négrier S, James ND, Kocak I,
Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P and Berns B: A
phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6
monoclonal antibody, in metastatic renal cell cancer. Br J Cancer.
103:1154–1162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fizazi K, De Bono JS, Flechon A,
Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT,
Cornfeld M and Hudes GR: Randomised phase II study of siltuximab
(CNTO 328), an anti-IL-6 monoclonal antibody, in combination with
mitoxantrone/prednisone versus mitoxantrone/prednisone alone in
metastatic castration-resistant prostate cancer. Eur J Cancer.
48:85–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Angevin E, Tabernero J, Elez E, Cohen SJ,
Bahleda R, van Laethem JL, Ottensmeier C, Lopez-Martin JA, Clive S,
Joly F, et al: A phase I/II, multiple-dose, dose-escalation study
of siltuximab, an anti-interleukin-6 monoclonal antibody, in
patients with advanced solid tumors. Clin Cancer Res. 20:2192–2204.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tanaka T, Narazaki M and Kishimoto T:
Therapeutic targeting of the interleukin-6 receptor. Annu Rev
Pharmacol Toxicol. 52:199–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Grivennikov S, Karin E, Terzic J, Mucida
D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H,
Eckmann L and Karin M: IL-6 and Stat3 are required for survival of
intestinal epithelial cells and development of colitis-associated
cancer. Cancer Cell. 15:103–113. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bollrath J, Phesse TJ, von Burstin VA,
Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T,
Canli O, Schwitalla S, et al: gp130-mediated Stat3 activation in
enterocytes regulates cell survival and cell-cycle progression
during colitis-associated tumorigenesis. Cancer Cell. 15:91–102.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rigby RJ, Simmons JG, Greenhalgh CJ,
Alexander WS and Lund PK: Suppressor of cytokine signaling 3
(SOCS3) limits damage-induced crypt hyper-proliferation and
inflammation-associated tumorigenesis in the colon. Oncogene.
26:4833–4841. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Waldner MJ, Wirtz S, Jefremow A, Warntjen
M, Neufert C, Atreya R, Becker C, Weigmann B, Vieth M, Rose-John S
and Neurath MF: VEGF receptor signaling links inflammation and
tumorigenesis in colitis-associated cancer. J Exp Med.
207:2855–2868. 2010. View Article : Google Scholar : PubMed/NCBI
|
